UP!
 |
|
|
Trading name
|
ARWR |
|---|---|
|
Type
|
Biopharmaceutical |
| Headquarters | Pasadena, CA |
|
Key people
|
Christopher Anzalone, Ph.D., President and Chief Executive Officer Bruce Given, M.D., Chief Operating Officer Ken Myszkowski, MBA, CPA, Chief Financial Officer |
| Website | http://arrowheadpharma.com/ |
Christopher Anzalone, Ph.D., President and Chief Executive Officer Bruce Given, M.D., Chief Operating Officer
Arrowhead Pharmaceuticals is a publicly traded (NASDAQ: ARWR) biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for Hepatitis B,the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease. The company has six products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2022-11-21 | Future report Set alerts | |
| Q3 2022 | 2022-08-04 | -0.68 | -0.68 |
| Q2 2022 | 2022-05-10 | 0.41 | 0.41 |
| Q1 2022 | 2022-02-02 | -0.60 | -0.60 |
| Q4 2021 | 2021-11-22 | -0.61 | -0.61 |
| Q3 2021 | 2021-08-05 | -0.29 | -0.29 |
| Q2 2021 | 2021-05-04 | -0.26 | -0.26 |
| Q1 2021 | 2021-02-04 | -0.20 | -0.20 |
| Q4 2020 | 2020-11-23 | 0.00 | 0.00 |
| Q3 2020 | 2020-08-05 | -0.13 | -0.13 |
| 2016-05-19 | Initiated Coverage | Chardan Capital | Buy | $12.00 |
| 2016-05-11 | Reiterated Rating | Jefferies Group | Hold | $4.75 |
| 2016-02-11 | Reiterated Rating | Piper Jaffray | Overweight | $20.00 to $13.00 |
| 2016-02-11 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $20.00 to $13.00 |
| 2016-02-10 | Lower Price Target | Jefferies Group | Hold | $7.00 to $4.00 |
| 2015-09-26 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-09-25 | Boost Price Target | Piper Jaffray | Overweight | $12.00 to $20.00 |
| 2015-08-05 | Reiterated Rating | RBC Capital | Hold | $9.00 |
| 2015-08-05 | Reiterated Rating | Royal Bank Of Canada | Hold | $9.00 |
| 2015-05-23 | Reiterated Rating | Jefferies Group | Hold | $9.00 to $7.50 |
| 2015-04-14 | Downgrade | Jefferies Group | Buy to Hold | $9.00 |
| 2015-01-22 | Downgrade | Deutsche Bank | Buy to Hold | $7.00 |
| 2015-01-22 | Downgrade | Deutsche Bank AG | Buy to Hold | $7.00 |
| 2014-10-08 | Downgrade | RBC Capital | Outperform to Sector Perform | $35.00 to $9.00 |
| 2014-10-08 | Lower Price Target | Deutsche Bank | Buy | $45.00 to $20.00 |
| 2014-09-17 | Reiterated Rating | RBC Capital | Outperform | |
| 2014-08-13 | Reiterated Rating | Deutsche Bank | Buy | |
| 2014-06-20 | Boost Price Target | Jefferies Group | Buy | $29.00 to $30.00 |
| 2014-05-07 | Lower Price Target | Jefferies Group | Buy | $30.00 to $29.00 |
| 2014-03-24 | Reiterated Rating | Deutsche Bank | Buy | |
| 2014-03-05 | Initiated Coverage | Deutsche Bank | Buy | $45.00 |
| 2014-03-04 | Initiated Coverage | RBC Capital | Buy to Outperform | $45.00 to $35.00 |
| 2014-03-03 | Initiated Coverage | Barclays | Overweight | |
| 2014-02-07 | Boost Price Target | Jefferies Group | $15.00 to $30.00 | |
| 2013-12-18 | Initiated Coverage | Jefferies Group | Buy | $15.00 |
| 2013-10-21 | Initiated Coverage | Piper Jaffray | Overweight | $12.00 to $7.87 |
| 2013-02-26 | Initiated | Dawson James | Buy | $4 |
| 2016-05-19 | Initiated Coverage | Chardan Capital | Buy | $12.00 |
| 2016-05-11 | Reiterated Rating | Jefferies Group | Hold | $4.75 |
| 2016-02-11 | Reiterated Rating | Piper Jaffray | Overweight | $20.00 to $13.00 |
| 2016-02-11 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $20.00 to $13.00 |
| 2016-02-10 | Lower Price Target | Jefferies Group | Hold | $7.00 to $4.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ARWR 213 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 12.09M |
| Vanguard Group, Inc | 10.15M |
| OPPENHEIMER FUNDS INC | 7.80M |
| STATE STREET CORP | 5.25M |
| BlackRock Fund Advisors | 2.95M |
| JPMORGAN CHASE & CO | 2.89M |
| ALLIANCEBERNSTEIN L.P. | 2.47M |
| FMR LLC | 2.45M |
| Invesco Ltd. | 2.22M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.89M |
| BlackRock Institutional Trust Company, N.A. | 1.83M |
| CREDIT SUISSE AG/ | 1.28M |
| NORTHERN TRUST CORP | 1.28M |
| FIRST MANHATTAN CO | 1.11M |
| SCHWAB CHARLES INVESTMENT MANAGEMENT INC | 1.10M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Anzalone Christopher Richard President and CEO | 3.72% (1968789) | ARWR / |
| GIVEN BRUCE D Chief Operating Officer | 1.72% (908356) | ARWR / |
| Myszkowski Kenneth Allen CFO | 0.59% (310815) | ARWR / |
| O'Brien Patrick General Counsel | 0.44% (235000) | ARWR / |
| PERRY MICHAEL S | 0.35% (185000) | APHB / ARWR / TGEN / |
| GIVEN DOUGLAS B | 0.29% (155000) | ARWR / |
| FRYKMAN EDWARD W | 0.28% (148852) | ACTG / ARWR / |
| Leone Peter Brian VP, Strategy & Program Mgmt | 0.25% (130000) | ARWR / |
| Ferrari Mauro | 0.12% (62768) | ARWR / |
| McKenney Charles | 0.08% (42220) | ARWR / |
| Waddill William D. | 0.05% (25000) | ARWR / CALA / OMED / PTGX / |
UM